Dual GIP and GLP-1 Receptor Agonists A newer class extends the incretin mimetic concept by targeting both GLP-1 and GIP receptors simultaneously
Cell studies show that BPA exposure directly causes a decrease in GLP-1 and insulin release through miR-338.[ref][ref] Related article: BPA, BPS, Genetics, and Detoxification Recap of your genes: FAQs: Do genetics affect how well semaglutide works
Bariatric surgery answers from those who have undergone bariatric surgery say there are challenges with nutritional supplements amongst the bariatric patient population
In a 2025 review, the authors describe this species as occupying an extraordinary niche in the human gut, and a model organism studied for its ability to modulate human health and gut microbiome structure.13 In animal studies, it has slowed the development and progression of diabetes , obesity , and irritable bowel disease .14 In human trials, it has helped participants reduce their BMI and improve their diabetic markers.12 Its effects on obesity and diabetes have been recreated in humans as well
Using an app or wearable device to monitor your physical activity can help you stay consistent and motivated
Tirzepatide injections (a dual GLP-1 and GIP receptor agonist) are $289/mo month-to-month, or from $249/mo on the 6-month plan, and oral tirzepatide is $349/mo month-to-month, or from $279/mo on the 6-month planall with zero price increases as you advance through your therapeutic dose range